Search This Blog

Friday, June 19, 2015

CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology (NYSE:LLY)

Encouraging Subgroup Findings Are Basis for New Phase III Trial



CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.